Loading
Sutro Biopharma, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Pauling David, was filed 16 Oct 2025.
Sutro Biopharma, Inc.: what insiders have been doing
Every trade that managers of Sutro Biopharma, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. In the past year (22 October 2025 to 22 October 2026), 23 filings came from 4 insiders.
Not one of the filings records a straightforward purchase or sale on the market. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
Across the 5,462 companies tracked on its exchange, the median is 28 filings; at 23 filings, this issuer sits below that mark. Over the whole record (from 2018), the tally stands at 10 purchases and 26 sales. The 10-K for the year ended 31 December 2025 shows 102.5 m USD of revenue and -191.1 m USD of net income.
No insider has bought Sutro Biopharma, Inc. shares on the open market in the past twelve months. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4.
In the same sector, recent insider purchases at Xenon Pharmaceuticals Inc. and Vivos Inc also feature in our signals. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
372
Thresholds
n/a
Buy Volume
€9M
10 ops. · all time
Sell Volume
€13M
26 ops. · all time
Who traded when
BuySaleConnie Matsui1 buy
David Pauling1 buy
Gregory K. Chow1 buy
Hans-Peter Gerber1 buy
Jane Chung1 buy
Since the insiders bought
- +29.4%Entry US$10.10 · Close at T+90 US$13.07
- +29.4%Entry US$10.10 · Close at T+90 US$13.07
- +29.4%Entry US$10.10 · Close at T+90 US$13.07
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Sutro Biopharma, Inc. Strong Buy (bullish), based on 13 analysts. Average price target: US$47.23.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$11.54
Analyst consensus
13 analystsStrong buy
US$10.00Target US$47.23(+309%)US$61.00
Income statement
RevenueUS$102.5M
EBITDA-US$141.8M-138% margin
Net income-US$191.1M-186.5% margin
Valuation
PER (forward)-1.9x
Beta1.50
Balance sheet & cash
Market capUS$191.3M
Total debtUS$15.7M
Free Cash Flow-US$178.9M
Profitability & ownership
ROA-36.1%
% insiders2.3%
% institutions99.0%
Last declaration on 22 September 2026
Declarations372 total
1,345 shares@ US$15.340.011% mcap60.6% of flowCommon StockSEC:0001992979-26-000004:1
3,750 shares0Common StockSEC:0001992979-26-000004:0
2,500 shares0Common StockSEC:0001761333-26-000005:0
277 shares@ US$21.3112.7% of flowCommon StockSEC:0002063633-26-000003:1
282 shares@ US$21.312.0% of flowCommon StockSEC:0001872398-26-000003:1
675 shares0Common StockSEC:0002063633-26-000003:0
788 shares0Common StockSEC:0001872398-26-000003:0
842 shares0Common StockSEC:0002063633-26-000002:1
2,356 shares0Common StockSEC:0002063633-26-000002:3
2,500 shares0Common StockSEC:0001872398-26-000002:1
7,750 shares0Common StockSEC:0001872398-26-000002:3
2,843 shares0Common StockSEC:0001992979-26-000002:2
551 shares@ US$20.4723.8% of flowCommon StockSEC:0002063633-26-000002:2
970 shares@ US$20.5542.2% of flowCommon StockSEC:0002063633-26-000002:4
1,271 shares@ US$20.478.5% of flowCommon StockSEC:0001872398-26-000002:2
2,779 shares@ US$20.5518.8% of flowCommon StockSEC:0001872398-26-000002:4
463 shares@ US$20.476.5% of flowCommon StockSEC:0001992979-26-000002:1
1,170 shares@ US$20.5516.6% of flowCommon StockSEC:0001992979-26-000002:3
500 shares0Common StockSEC:0002063633-26-000002:0
1,125 shares0Common StockSEC:0001992979-26-000002:0
688 shares0Common StockSEC:0001872398-26-000002:0
894 shares@ US$8.022.4% of flowCommon StockSEC:0001872398-25-000005:1
2,500 shares0Common StockSEC:0001872398-25-000005:0
17,000 shares@ US$0.800439.4% of flowCommon StockSEC:0001992979-25-000004:0
Canonical exit: 13 Jan 2026 (T+90)
12,504 shares@ US$0.7992100.0% of flowCommon StockSEC:0002063633-25-000004:0
Canonical exit: 13 Jan 2026 (T+90)
25 of 372 declarations
About Sutro Biopharma, Inc.
Sutro Biopharma, Inc. (ticker: STRO) is a U.S.-listed biotechnology company trading on NASDAQ in the United States, with headquarters in South San Francisco, California. Founded in 2003 under the original name Fundamental Applied Biology, Inc. and later renamed Sutro Biopharma, the company has built its identity around next-generation oncology innovation. Its core technological foundation is the proprietary cell-free protein synthesis platform XpressCF® paired with the site-specific conjugation platform XpressCF+®, which together are designed to enable the discovery and manufacturing of more homogeneous, potentially more differentiated antibody-drug conjugates (ADCs).
Sutro’s business is primarily focused on the development of oncology assets, while also monetizing its platform through selective partnerships with pharmaceutical and biotechnology companies. The company’s historical significance comes from its ability to generate internally discovered programs, including STRO-001 and STRO-002 (luvelta), which helped validate its technology and demonstrated the breadth of the platform. In recent periods, Sutro has sharpened its strategic focus around a more concentrated pipeline, with STRO-004 as its highest-priority wholly owned asset, alongside additional programs such as STRO-006 and STRO-227 moving through preclinical and regulatory-enabling work.
Read moreShow less
From a competitive standpoint, Sutro operates in the highly contested ADC market, where differentiation depends on payload design, target selection, tolerability, manufacturability, and clinical execution. The company’s investment case is based on the idea that its site-specific and novel-format ADC approach can generate better therapeutic profiles and a more scalable manufacturing process than conventional stochastic conjugation methods. That said, it remains a clinical-stage biotech with the usual risks: clinical readouts may disappoint, regulatory timelines can shift, and financing needs can affect shareholder dilution.
Geographically, Sutro is largely U.S.-based, with its corporate and research footprint rooted in California, but its commercial and scientific ambitions are global because oncology development, trial recruitment, and partnering are international in nature. Recent developments have centered on the continued advancement of the pipeline, including ongoing Phase 1 work for STRO-004, IND-enabling activity for STRO-006 and STRO-227, and recent quarterly and full-year financial updates in 2025 and 2026. The company also completed a significant equity financing in early 2026 to strengthen its balance sheet and extend operating visibility. For French-speaking investors, STRO should be viewed as a high-risk, high-upside biotech story: scientifically interesting, strategically focused, but still dependent on clinical delivery and capital discipline.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
